Prospective, Randomized, Blinded Phase II Pharmacokinetic/Pharmacodynamic Study of the Efficacy and Tolerability of Levofloxacin in Combination With Optimized Background Regimen for the Treatment of MDR-TB
Phase of Trial: Phase II
Latest Information Update: 31 Jul 2017
At a glance
- Drugs Levofloxacin (Primary) ; Antituberculars
- Indications Pulmonary tuberculosis
- Focus Therapeutic Use
- Acronyms Opti-Q
- 27 Jul 2017 Status changed from active, no longer recruiting to completed.
- 27 Feb 2017 Planned End Date changed from 1 Jul 2017 to 1 Aug 2017.
- 27 Feb 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Jul 2017.